BioSyent (CVE:RX) Director Stephen Edwin William Wilton Sells 805 Shares of Stock

BioSyent Inc. (CVE:RX) Director Stephen Edwin William Wilton sold 805 shares of BioSyent stock in a transaction on Friday, August 28th. The stock was sold at an average price of C$15.84, for a total transaction of C$12,751.20. Following the sale, the director directly owned 7,876 shares in the company, valued at approximately C$124,755.84. This trade represents a 9.27% decrease in their position.

BioSyent Price Performance

Shares of CVE RX traded down C$0.20 during mid-day trading on Friday, reaching C$15.75. The company’s stock had a trading volume of 34,158 shares, compared to its average volume of 8,011. The stock has a 50-day moving average of C$14.74 and a two-hundred day moving average of C$14.71. The stock has a market capitalization of C$178.18 million, a P/E ratio of 18.44 and a beta of 1.00. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07. BioSyent Inc. has a 1-year low of C$10.65 and a 1-year high of C$16.00.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.